Merck KGaA Follows Pfizer With Archemix Deal For Aptamer-Based Therapeutics
This article was originally published in The Pink Sheet Daily
Executive Summary
German drug maker's new subsidiary, Merck Serono, will oversee development of aptamer-based drugs to treat cancer.
You may also be interested in...
Takeda, Merck KGaA Sign Aptamer Development Deals With Archemix
Archemix has signed separate agreements with Takeda and Merck KGaA to develop therapeutics based on aptamers, the firms announced June 11
Takeda, Merck KGaA Sign Aptamer Development Deals With Archemix
Archemix gets $6 million up-front in Takeda deal; Merck agrees to make $29.8 million equity investment in Cambridge, Mass. company.
Takeda, Merck KGaA Sign Aptamer Development Deals With Archemix
Archemix gets $6 million up-front in Takeda deal; Merck agrees to make $29.8 million equity investment in Cambridge, Mass. company.